Comment on: Kim et al. Deficiency for costimulatory receptor 4-1BB protects against obesity-induced inflammation and metabolic disorders. Diabetes 2011;60:3159-3168

Autores
Gomez-Mejiba, Sandra Esther; Ramirez, Dario
Año de publicación
2012
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
In the December 2011 issue of Diabetes, Kim et al. [1] reported that 4-1BB (CD137/TNFRSF9) deficiency protected against high fat diet (HFD)-induced obesity, glucose intolerance and fatty liver disease. They found that 4-1BB deficiency reduced number and activation of macrophages/CD8+ T cells/Th1 cells into adipose tissue, reduced circulating pro-inflammatory cytokines, and improved insulin sensitivity/liver pathology with respect to wild-type animals fed the same diet. This is an important advance in the field because antagonism of the 4-1BB/4-1BB ligand interaction (e.g., modulating its expression, blocking receptor/ligand interaction and interfering signaling) could help reduce macrophage infiltration and adipose tissue inflammation in obesity. However, in a paper published by the same laboratories in 2010 in Endocrinology [2] they found that 4-1BB stimulation with an agonistic antibody reduced weight gain and adiposity, increased energy expenditure and improved insulin tolerance and fatty liver disease in HFD-fed mice and genetically obese mice. The authors suggest that these effects would have been caused by 4-1BB induced expansion/activation of CD8+ T-cells and consequent increased energy expenditure. We are puzzled to understand this apparent discrepancy between these two elegant studies [1, 2] and why the first study was not discussed in the Diabetes paper, which would help us understand the rationale of these apparently opposite results between these studies.   Inflammation and dysfunction of adipose tissue have emerged as important targets to reduce systemic inflammation and insulin resistance (IR) associated to obesity [3]. As supported by an extensive body of evidence, most of the inflammatory cytokines produced by inflamed adipose tissue derives from fat-infiltrating and classically-activated M1 macrophages [3]. This infiltration and activation of macrophages into the stressed adipose tissue in obesity play critical roles in metabolic alterations associated to obesity [3]. Nishimura’s work [4] has highlighted the importance of CD8+ T-cells in monocyte infiltration, and differentiation and survival as macrophages into the obese adipose tissue [4]. Moreover, 4-1BB expression increases upon activation in T-cells and in inflamed vessel walls, where it promotes monocyte migration and macrophage differentiation, survival and activation [5]. This agrees with Kim’s data regarding increased expression of 4-1BB in adipose tissue of obese wild type mice [1]. Therefore and opposite to what reported in [2], we would have expected that administration of an antibody that agonizes 4-1BB signaling in obese wild-type mice would increase activation of CD8+ cells and promote more macrophage infiltration and activation into the fat tissue. To facilitate the advancement in the field it is necessary to have a clearer picture of how agonists or antagonists of 4-1BB and/or 4-1BB ligand change macrophage recruitment and activation in the metabolically-stressed adipose tissue in obesity. Understanding of these processes will ensure mechanism-based interventions to reduce macrophage infiltration and consequent adipose tissue inflammation—a leading cause of metabolic complications of obesity.
Fil: Gomez-Mejiba, Sandra Esther. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - San Luis. Instituto Multidisciplinario de Investigaciones Biológicas de San Luis. Universidad Nacional de San Luis. Facultad de Ciencias Físico Matemáticas y Naturales. Instituto Multidisciplinario de Investigaciones Biológicas de San Luis; Argentina
Fil: Ramirez, Dario. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - San Luis. Instituto Multidisciplinario de Investigaciones Biológicas de San Luis. Universidad Nacional de San Luis. Facultad de Ciencias Físico Matemáticas y Naturales. Instituto Multidisciplinario de Investigaciones Biológicas de San Luis; Argentina
Materia
CD137
MACROPHAGE
ADIPOSE TISSUE INFLAMMATION
INSULIN RESISTANCE
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/147960

id CONICETDig_0742b3eeedb0bfead6cf92e0f1c9d0c0
oai_identifier_str oai:ri.conicet.gov.ar:11336/147960
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Comment on: Kim et al. Deficiency for costimulatory receptor 4-1BB protects against obesity-induced inflammation and metabolic disorders. Diabetes 2011;60:3159-3168Gomez-Mejiba, Sandra EstherRamirez, DarioCD137MACROPHAGEADIPOSE TISSUE INFLAMMATIONINSULIN RESISTANCEhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3In the December 2011 issue of Diabetes, Kim et al. [1] reported that 4-1BB (CD137/TNFRSF9) deficiency protected against high fat diet (HFD)-induced obesity, glucose intolerance and fatty liver disease. They found that 4-1BB deficiency reduced number and activation of macrophages/CD8+ T cells/Th1 cells into adipose tissue, reduced circulating pro-inflammatory cytokines, and improved insulin sensitivity/liver pathology with respect to wild-type animals fed the same diet. This is an important advance in the field because antagonism of the 4-1BB/4-1BB ligand interaction (e.g., modulating its expression, blocking receptor/ligand interaction and interfering signaling) could help reduce macrophage infiltration and adipose tissue inflammation in obesity. However, in a paper published by the same laboratories in 2010 in Endocrinology [2] they found that 4-1BB stimulation with an agonistic antibody reduced weight gain and adiposity, increased energy expenditure and improved insulin tolerance and fatty liver disease in HFD-fed mice and genetically obese mice. The authors suggest that these effects would have been caused by 4-1BB induced expansion/activation of CD8+ T-cells and consequent increased energy expenditure. We are puzzled to understand this apparent discrepancy between these two elegant studies [1, 2] and why the first study was not discussed in the Diabetes paper, which would help us understand the rationale of these apparently opposite results between these studies.   Inflammation and dysfunction of adipose tissue have emerged as important targets to reduce systemic inflammation and insulin resistance (IR) associated to obesity [3]. As supported by an extensive body of evidence, most of the inflammatory cytokines produced by inflamed adipose tissue derives from fat-infiltrating and classically-activated M1 macrophages [3]. This infiltration and activation of macrophages into the stressed adipose tissue in obesity play critical roles in metabolic alterations associated to obesity [3]. Nishimura’s work [4] has highlighted the importance of CD8+ T-cells in monocyte infiltration, and differentiation and survival as macrophages into the obese adipose tissue [4]. Moreover, 4-1BB expression increases upon activation in T-cells and in inflamed vessel walls, where it promotes monocyte migration and macrophage differentiation, survival and activation [5]. This agrees with Kim’s data regarding increased expression of 4-1BB in adipose tissue of obese wild type mice [1]. Therefore and opposite to what reported in [2], we would have expected that administration of an antibody that agonizes 4-1BB signaling in obese wild-type mice would increase activation of CD8+ cells and promote more macrophage infiltration and activation into the fat tissue. To facilitate the advancement in the field it is necessary to have a clearer picture of how agonists or antagonists of 4-1BB and/or 4-1BB ligand change macrophage recruitment and activation in the metabolically-stressed adipose tissue in obesity. Understanding of these processes will ensure mechanism-based interventions to reduce macrophage infiltration and consequent adipose tissue inflammation—a leading cause of metabolic complications of obesity.Fil: Gomez-Mejiba, Sandra Esther. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - San Luis. Instituto Multidisciplinario de Investigaciones Biológicas de San Luis. Universidad Nacional de San Luis. Facultad de Ciencias Físico Matemáticas y Naturales. Instituto Multidisciplinario de Investigaciones Biológicas de San Luis; ArgentinaFil: Ramirez, Dario. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - San Luis. Instituto Multidisciplinario de Investigaciones Biológicas de San Luis. Universidad Nacional de San Luis. Facultad de Ciencias Físico Matemáticas y Naturales. Instituto Multidisciplinario de Investigaciones Biológicas de San Luis; ArgentinaAmerican Diabetes Association2012-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/147960Gomez-Mejiba, Sandra Esther; Ramirez, Dario; Comment on: Kim et al. Deficiency for costimulatory receptor 4-1BB protects against obesity-induced inflammation and metabolic disorders. Diabetes 2011;60:3159-3168; American Diabetes Association; Diabetes; 61; 7; 7-2012; e6 - e60012-1797CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.2337/db12-0128info:eu-repo/semantics/altIdentifier/url/https://diabetes.diabetesjournals.org/content/61/7/e6info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:26:49Zoai:ri.conicet.gov.ar:11336/147960instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:26:49.621CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Comment on: Kim et al. Deficiency for costimulatory receptor 4-1BB protects against obesity-induced inflammation and metabolic disorders. Diabetes 2011;60:3159-3168
title Comment on: Kim et al. Deficiency for costimulatory receptor 4-1BB protects against obesity-induced inflammation and metabolic disorders. Diabetes 2011;60:3159-3168
spellingShingle Comment on: Kim et al. Deficiency for costimulatory receptor 4-1BB protects against obesity-induced inflammation and metabolic disorders. Diabetes 2011;60:3159-3168
Gomez-Mejiba, Sandra Esther
CD137
MACROPHAGE
ADIPOSE TISSUE INFLAMMATION
INSULIN RESISTANCE
title_short Comment on: Kim et al. Deficiency for costimulatory receptor 4-1BB protects against obesity-induced inflammation and metabolic disorders. Diabetes 2011;60:3159-3168
title_full Comment on: Kim et al. Deficiency for costimulatory receptor 4-1BB protects against obesity-induced inflammation and metabolic disorders. Diabetes 2011;60:3159-3168
title_fullStr Comment on: Kim et al. Deficiency for costimulatory receptor 4-1BB protects against obesity-induced inflammation and metabolic disorders. Diabetes 2011;60:3159-3168
title_full_unstemmed Comment on: Kim et al. Deficiency for costimulatory receptor 4-1BB protects against obesity-induced inflammation and metabolic disorders. Diabetes 2011;60:3159-3168
title_sort Comment on: Kim et al. Deficiency for costimulatory receptor 4-1BB protects against obesity-induced inflammation and metabolic disorders. Diabetes 2011;60:3159-3168
dc.creator.none.fl_str_mv Gomez-Mejiba, Sandra Esther
Ramirez, Dario
author Gomez-Mejiba, Sandra Esther
author_facet Gomez-Mejiba, Sandra Esther
Ramirez, Dario
author_role author
author2 Ramirez, Dario
author2_role author
dc.subject.none.fl_str_mv CD137
MACROPHAGE
ADIPOSE TISSUE INFLAMMATION
INSULIN RESISTANCE
topic CD137
MACROPHAGE
ADIPOSE TISSUE INFLAMMATION
INSULIN RESISTANCE
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv In the December 2011 issue of Diabetes, Kim et al. [1] reported that 4-1BB (CD137/TNFRSF9) deficiency protected against high fat diet (HFD)-induced obesity, glucose intolerance and fatty liver disease. They found that 4-1BB deficiency reduced number and activation of macrophages/CD8+ T cells/Th1 cells into adipose tissue, reduced circulating pro-inflammatory cytokines, and improved insulin sensitivity/liver pathology with respect to wild-type animals fed the same diet. This is an important advance in the field because antagonism of the 4-1BB/4-1BB ligand interaction (e.g., modulating its expression, blocking receptor/ligand interaction and interfering signaling) could help reduce macrophage infiltration and adipose tissue inflammation in obesity. However, in a paper published by the same laboratories in 2010 in Endocrinology [2] they found that 4-1BB stimulation with an agonistic antibody reduced weight gain and adiposity, increased energy expenditure and improved insulin tolerance and fatty liver disease in HFD-fed mice and genetically obese mice. The authors suggest that these effects would have been caused by 4-1BB induced expansion/activation of CD8+ T-cells and consequent increased energy expenditure. We are puzzled to understand this apparent discrepancy between these two elegant studies [1, 2] and why the first study was not discussed in the Diabetes paper, which would help us understand the rationale of these apparently opposite results between these studies.   Inflammation and dysfunction of adipose tissue have emerged as important targets to reduce systemic inflammation and insulin resistance (IR) associated to obesity [3]. As supported by an extensive body of evidence, most of the inflammatory cytokines produced by inflamed adipose tissue derives from fat-infiltrating and classically-activated M1 macrophages [3]. This infiltration and activation of macrophages into the stressed adipose tissue in obesity play critical roles in metabolic alterations associated to obesity [3]. Nishimura’s work [4] has highlighted the importance of CD8+ T-cells in monocyte infiltration, and differentiation and survival as macrophages into the obese adipose tissue [4]. Moreover, 4-1BB expression increases upon activation in T-cells and in inflamed vessel walls, where it promotes monocyte migration and macrophage differentiation, survival and activation [5]. This agrees with Kim’s data regarding increased expression of 4-1BB in adipose tissue of obese wild type mice [1]. Therefore and opposite to what reported in [2], we would have expected that administration of an antibody that agonizes 4-1BB signaling in obese wild-type mice would increase activation of CD8+ cells and promote more macrophage infiltration and activation into the fat tissue. To facilitate the advancement in the field it is necessary to have a clearer picture of how agonists or antagonists of 4-1BB and/or 4-1BB ligand change macrophage recruitment and activation in the metabolically-stressed adipose tissue in obesity. Understanding of these processes will ensure mechanism-based interventions to reduce macrophage infiltration and consequent adipose tissue inflammation—a leading cause of metabolic complications of obesity.
Fil: Gomez-Mejiba, Sandra Esther. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - San Luis. Instituto Multidisciplinario de Investigaciones Biológicas de San Luis. Universidad Nacional de San Luis. Facultad de Ciencias Físico Matemáticas y Naturales. Instituto Multidisciplinario de Investigaciones Biológicas de San Luis; Argentina
Fil: Ramirez, Dario. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - San Luis. Instituto Multidisciplinario de Investigaciones Biológicas de San Luis. Universidad Nacional de San Luis. Facultad de Ciencias Físico Matemáticas y Naturales. Instituto Multidisciplinario de Investigaciones Biológicas de San Luis; Argentina
description In the December 2011 issue of Diabetes, Kim et al. [1] reported that 4-1BB (CD137/TNFRSF9) deficiency protected against high fat diet (HFD)-induced obesity, glucose intolerance and fatty liver disease. They found that 4-1BB deficiency reduced number and activation of macrophages/CD8+ T cells/Th1 cells into adipose tissue, reduced circulating pro-inflammatory cytokines, and improved insulin sensitivity/liver pathology with respect to wild-type animals fed the same diet. This is an important advance in the field because antagonism of the 4-1BB/4-1BB ligand interaction (e.g., modulating its expression, blocking receptor/ligand interaction and interfering signaling) could help reduce macrophage infiltration and adipose tissue inflammation in obesity. However, in a paper published by the same laboratories in 2010 in Endocrinology [2] they found that 4-1BB stimulation with an agonistic antibody reduced weight gain and adiposity, increased energy expenditure and improved insulin tolerance and fatty liver disease in HFD-fed mice and genetically obese mice. The authors suggest that these effects would have been caused by 4-1BB induced expansion/activation of CD8+ T-cells and consequent increased energy expenditure. We are puzzled to understand this apparent discrepancy between these two elegant studies [1, 2] and why the first study was not discussed in the Diabetes paper, which would help us understand the rationale of these apparently opposite results between these studies.   Inflammation and dysfunction of adipose tissue have emerged as important targets to reduce systemic inflammation and insulin resistance (IR) associated to obesity [3]. As supported by an extensive body of evidence, most of the inflammatory cytokines produced by inflamed adipose tissue derives from fat-infiltrating and classically-activated M1 macrophages [3]. This infiltration and activation of macrophages into the stressed adipose tissue in obesity play critical roles in metabolic alterations associated to obesity [3]. Nishimura’s work [4] has highlighted the importance of CD8+ T-cells in monocyte infiltration, and differentiation and survival as macrophages into the obese adipose tissue [4]. Moreover, 4-1BB expression increases upon activation in T-cells and in inflamed vessel walls, where it promotes monocyte migration and macrophage differentiation, survival and activation [5]. This agrees with Kim’s data regarding increased expression of 4-1BB in adipose tissue of obese wild type mice [1]. Therefore and opposite to what reported in [2], we would have expected that administration of an antibody that agonizes 4-1BB signaling in obese wild-type mice would increase activation of CD8+ cells and promote more macrophage infiltration and activation into the fat tissue. To facilitate the advancement in the field it is necessary to have a clearer picture of how agonists or antagonists of 4-1BB and/or 4-1BB ligand change macrophage recruitment and activation in the metabolically-stressed adipose tissue in obesity. Understanding of these processes will ensure mechanism-based interventions to reduce macrophage infiltration and consequent adipose tissue inflammation—a leading cause of metabolic complications of obesity.
publishDate 2012
dc.date.none.fl_str_mv 2012-07
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/147960
Gomez-Mejiba, Sandra Esther; Ramirez, Dario; Comment on: Kim et al. Deficiency for costimulatory receptor 4-1BB protects against obesity-induced inflammation and metabolic disorders. Diabetes 2011;60:3159-3168; American Diabetes Association; Diabetes; 61; 7; 7-2012; e6 - e6
0012-1797
CONICET Digital
CONICET
url http://hdl.handle.net/11336/147960
identifier_str_mv Gomez-Mejiba, Sandra Esther; Ramirez, Dario; Comment on: Kim et al. Deficiency for costimulatory receptor 4-1BB protects against obesity-induced inflammation and metabolic disorders. Diabetes 2011;60:3159-3168; American Diabetes Association; Diabetes; 61; 7; 7-2012; e6 - e6
0012-1797
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.2337/db12-0128
info:eu-repo/semantics/altIdentifier/url/https://diabetes.diabetesjournals.org/content/61/7/e6
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv American Diabetes Association
publisher.none.fl_str_mv American Diabetes Association
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846781830464798720
score 12.982451